|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07H 19/067 | |
| A61K 31/7072 | |||
| A61P 31/14 | |||
| C07B 59/00 |
| (11) | Number of the document | 2984097 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14722955.3 |
| Date of filing the European patent application | 2014-04-14 | |
| (97) | Date of publication of the European application | 2016-02-17 |
| (45) | Date of publication and mention of the grant of the patent | 2017-03-29 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/034018 |
| Date | 2014-04-14 |
| (87) | Number | WO 2014/169278 |
| Date | 2014-10-16 |
| (30) | Number | Date | Country code |
| 201361811464 P | 2013-04-12 | US |
| (72) |
DESHPANDE, Milind, US
WILES, Jason Allan, US
HASHIMOTO, Akihiro, US
PHADKE, Avinash, US
|
| (73) |
Achillion Pharmaceuticals, Inc.,
300 George Street, New Haven, CT 06511,
US
|
| (54) | HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV |
| HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV |